PROteolysis TArgeting Chimeras (PROTACs) and beyond: targeted degradation as a new path to fight microbial pathogens

Abstract

Targeted degradation is emerging as a new therapeutic approach in the treatment of different diseases. It allows hijacking the cellular pathways deputed to protein or nucleic acid homeostasis to degrade a target macromolecule of interest involved in a pathogenic process. In the last decades, targeted protein degradation has been widely applied for the treatment of cancer or neurodegenerative disorders and some of such therapies are already in clinical use. More recently, therapeutic degraders such as PROTACs, LYTACs, HyTs, BacPROTACs, and others have also been explored in the field of antimicrobial and antiviral drug discovery. The peculiar mechanism of action, along with the opportunity to degrade both microbial and host targets, holds great promise for overcoming some limitations of classic antimicrobials, e.g. drug resistance, as well as for increasing the potency of current therapies. With a focus on the antimicrobial field, this Review aims at providing a comprehensive, state-of-the-art description of targeted degradation mechanisms and strategies developed so far, as well as to discuss advantages, disadvantages, and caveats of this innovative approach for combating infectious diseases.